体外留置导管经支气管动脉大剂量灌注免疫及化疗药物治疗Ⅲ期非小细胞肺癌的临床疗效观察  

Bronchial Artery Perfusion of Large Dose Immunologic and Chemotherapeutic Agents via Indwelling Catheter: Effect on Ⅲ Advanced Primary NSCLC

作　　者：胡大武[1] 陈君辉[1] 段天红[1] 杨永莲[1] 文永君[1] 曹蓉[1] 杨玉波[1] 吴辉[1] 

机构地区：[1]四川省肿瘤医院影像科介入病区,成都610041

出　　处：《临床放射学杂志》2003年第2期140-142,共3页Journal of Clinical Radiology

摘　　要：目的　评价体外留置导管经支气管动脉大剂量灌注免疫及化疗药物治疗Ⅲ期非小细胞肺癌的临床疗效及安全性。资料与方法　 39例经病理组织学证实的Ⅲ期非小细胞肺癌患者随机分为免疫化疗组和对照组 ,分别进行经体外留置导管支气管动脉灌注免疫及化疗药物和单纯支气管动脉灌注化疗药物 3次。结果　大剂量灌注免疫化疗组和单纯支气管动脉灌注化疗组的近期有效率分别为 90 %和 6 3% ,两组间具有显著性差异 (P <0 .0 5 )、中位生存期分别为 17.6个月和 10 .3个月 ,有显著性差异 (P <0 .0 1) ,无脊髓动脉损伤等严重并发症。结论　经体外留置导管行支气管动脉大剂量灌注免疫及化疗药物治疗Ⅲ期非小细胞肺癌在严格掌握手术指征的条件下是安全、可行的 。Objective To evaluate bronchial artery perfusion of large dose immunologic and chemotherapeutic agents via indwelling catheter in treating III advanced primary non-small cell lung cancer (NSCLC).Materials and Methods Thirty nine patients with pathologically proved Ⅲ advanced primary NSCLC were randomly divided into study group, receiving immunologic and chemotherapeutic agents perfusion via indwelling catheter for 3 times, and control group, simply receiving bronchial arterial chemotherapeutic perfusion for 3 times. The clinical results were compared.Results Short term effective rate and the median survival period for the study group and control group was 90%, 17.6 months and 63%, 10.3 months (P<0.05 and P<0.01), respectively. No spinal artery damage or other serious complications occurred.Conclusion Under strictly controlling the therapeutic indications, this technique is safe and feasible for the treatment of Ⅲ advanced primary NSCLC, with better clinical results than simple bronchial arterial chemotherapeutic perfusion.

关 键 词：体外留置导管 药物治疗 肺癌 临床疗效 安全性 支气管动脉灌注 非小细胞 大剂量 免疫化疗 

分 类 号：R734.2[医药卫生—肿瘤]